| Antibody-mediated dysfunction | Anti-CASPR2 IgG antibodies bind to the extracellular domain of CASPR2[@antibodies] |
| Pathogenic effects | Antibodies disrupt CASPR2 function without causing significant neuronal death |
| Intrathecal synthesis | Some patients have intrathecal antibody production |
| T-cell involvement | Both humoral and cellular immune mechanisms contribute[@antibodies] |
| Complement activation | May play a role in neuroinflammation |
| Thymoma | Most commonly associated (~15-20% of cases)[@antibodies], [@morvan] |
| Databases | OMIMOrphanetClinicalTrialsPubMed |